67,34 <%= Resources.Global.txtUp %>
Opdateret 22-06-2018
Ændring % 0,33% Stigning i aktiekurs
Ændring 0,22 Stigning i aktiekurs
Volume 298.992
Høj 67,44
Lav 66,80
Åben 66,94
ISIN BE0003739530
Seneste luk 67,12
# af aktier 194,51M
Markedsværdi 13.098M EUR
I dag

Market closed
UCB
Markedet er lukket, åbner klokken 09:00
 
Kursudvikling Seneste 1 uge 1 måned 3 mdr 6 mdr 1 år
 
  67,34 0,8% Stigning i aktiekurs 2,7% Stigning i aktiekurs 3,2% Stigning i aktiekurs 2,1% Stigning i aktiekurs 8,6% Stigning i aktiekurs
Powered by TradingView

Firmaprofil

UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, both of which have lost patent protection. The firm's newer key drugs include Cimzia (rheumatoid arthritis, psoriatic arthritis, and Crohn's disease), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), and Briviact (epilepsy).

Copyright Euroinvestor A/S 2018  Disclaimer  |  Cookie- og privatlivspolitik  |  Persondatapolitik
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
23. juni 2018 23:26:33
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180619.1 - EUROWEB7 - 2018-06-23 23:26:33 - 2018-06-23 23:26:33 - 1 - Website: OKAY